Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents (levos-milr)
Hypertension, Pulmonary, Cardiac Failure, Pulmonary Vascular Resistance Abnormality
About this trial
This is an interventional prevention trial for Hypertension, Pulmonary focused on measuring pulmonary vascular resistance, pulmonary hypertension, vasodilators, milrinone, levosimendan, cardiopulmonary bypass
Eligibility Criteria
Inclusion Criteria:
- patients with pulmonary hypertension due to left ventricular dysfunction based on echocardiographic diagnosis preoperatively
- elective cardiac surgery
Exclusion Criteria:
- primary pulmonary hypertension
- thromboembolic disease
- chronic obstructive pulmonary disease
- emergency surgery
- redo surgery
- inability to consent to the study
Sites / Locations
- Onassis Cardiac Surgery CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Intravenous administration of Levosimendan at a dosage of 6 mcg/kg after induction of anesthesia
Inhalational administration of Milrinone at a dosage of 50 mcg/kg after induction of anesthesia
in this group, 6 mcg/kg of levosimendan will be administered intravenously after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
in this group, 50 mcg/kg of milrinone will be administered via inhalation after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass